September, 2020 |
Launched Ilumya® (tildrakizumab) for the treatment of plaque psoriasis, which is the first new biologics for Sun Pharma Japan in the Japanese market. |
---|---|
January, 2020 |
Merged with Pola Pharma Inc. |
September, 2016 |
Announced the succession for manufacturing and marketing authorization for 14 long listed brands from Novartis Pharma K.K. |
March, 2012 |
Sun Pharma Japan Limited was established in Japan |